Abstract
41 patients with various solid tumors were treated with a combination of adriamycin and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU). Adriamycin was given every 3 wk at a dose ranging from 40-75 mg/m2, and CCNU was given every 6 wk at a dose ranging from 65-125 mg/m2. The cases of 33 of the 41 patients were considered evaluable. Three patients had complete responses and 11 had partial (greater than 50%) remissions for a response rate of 34% considering all patients treated, or 42% considering only those with evaluable cases. Responses were noted in patients with cancer of the breast (8 of 13), squamous cell carcinoma of the head and neck (3 of 6), malignant melanoma (1 of 8), undifferentiated carcinoma with unknown primary site (1 of 5), and lymphoma (1 of 4). The combination was well tolerated; its main toxic effects were vomiting, alopecia, and hematologic depression. With this combination there were 2 nadirs of myelosuppression: one occurred on Day 15 and the other occurred on Day 36. Prolonged thrombocytopenia was occasionally seen after multiple doses of CCNU.
| Original language | English (US) |
|---|---|
| Title of host publication | CANCER CHEMOTHER.REP. |
| Pages | 437-445 |
| Number of pages | 9 |
| Volume | 57 |
| Edition | 4 |
| State | Published - 1973 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Combination chemotherapy with adriamycin (NSC 123127) and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU; NSC 79037). / Einhorn, L. H.; Livingston, Robert B; Gottlieb, J. A.
CANCER CHEMOTHER.REP.. Vol. 57 4. ed. 1973. p. 437-445.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Combination chemotherapy with adriamycin (NSC 123127) and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU; NSC 79037)
AU - Einhorn, L. H.
AU - Livingston, Robert B
AU - Gottlieb, J. A.
PY - 1973
Y1 - 1973
N2 - 41 patients with various solid tumors were treated with a combination of adriamycin and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU). Adriamycin was given every 3 wk at a dose ranging from 40-75 mg/m2, and CCNU was given every 6 wk at a dose ranging from 65-125 mg/m2. The cases of 33 of the 41 patients were considered evaluable. Three patients had complete responses and 11 had partial (greater than 50%) remissions for a response rate of 34% considering all patients treated, or 42% considering only those with evaluable cases. Responses were noted in patients with cancer of the breast (8 of 13), squamous cell carcinoma of the head and neck (3 of 6), malignant melanoma (1 of 8), undifferentiated carcinoma with unknown primary site (1 of 5), and lymphoma (1 of 4). The combination was well tolerated; its main toxic effects were vomiting, alopecia, and hematologic depression. With this combination there were 2 nadirs of myelosuppression: one occurred on Day 15 and the other occurred on Day 36. Prolonged thrombocytopenia was occasionally seen after multiple doses of CCNU.
AB - 41 patients with various solid tumors were treated with a combination of adriamycin and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU). Adriamycin was given every 3 wk at a dose ranging from 40-75 mg/m2, and CCNU was given every 6 wk at a dose ranging from 65-125 mg/m2. The cases of 33 of the 41 patients were considered evaluable. Three patients had complete responses and 11 had partial (greater than 50%) remissions for a response rate of 34% considering all patients treated, or 42% considering only those with evaluable cases. Responses were noted in patients with cancer of the breast (8 of 13), squamous cell carcinoma of the head and neck (3 of 6), malignant melanoma (1 of 8), undifferentiated carcinoma with unknown primary site (1 of 5), and lymphoma (1 of 4). The combination was well tolerated; its main toxic effects were vomiting, alopecia, and hematologic depression. With this combination there were 2 nadirs of myelosuppression: one occurred on Day 15 and the other occurred on Day 36. Prolonged thrombocytopenia was occasionally seen after multiple doses of CCNU.
UR - http://www.scopus.com/inward/record.url?scp=0015732291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015732291&partnerID=8YFLogxK
M3 - Chapter
VL - 57
SP - 437
EP - 445
BT - CANCER CHEMOTHER.REP.
ER -